Ascendis Pharma A/S (ASND)
275.39
+8.32
(+3.12%)
USD |
NASDAQ |
Nov 13, 16:00
275.04
-0.35
(-0.13%)
After-Hours: 19:59
Ascendis Pharma Enterprise Value : 17.48B for Nov. 13, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2026 | 17.48B |
| November 12, 2026 | 16.93B |
| November 11, 2026 | 16.42B |
| November 10, 2026 | 16.24B |
| November 09, 2026 | 16.46B |
| November 06, 2026 | 16.26B |
| November 05, 2026 | 16.04B |
| November 04, 2026 | 16.33B |
| November 03, 2026 | 15.82B |
| November 02, 2026 | 15.75B |
| October 30, 2026 | 15.90B |
| October 29, 2026 | 16.01B |
| October 28, 2026 | 15.78B |
| October 27, 2026 | 15.54B |
| October 26, 2026 | 15.49B |
| October 23, 2026 | 15.38B |
| October 22, 2026 | 15.35B |
| October 21, 2026 | 15.08B |
| October 20, 2026 | 14.78B |
| October 19, 2026 | 14.50B |
| October 16, 2026 | 14.19B |
| October 15, 2026 | 14.28B |
| October 14, 2026 | 14.30B |
| October 13, 2026 | 14.05B |
| October 12, 2026 | 14.30B |
| Date | Value |
|---|---|
| October 09, 2026 | 14.45B |
| October 08, 2026 | 14.02B |
| October 07, 2026 | 14.40B |
| October 06, 2026 | 14.24B |
| October 05, 2026 | 14.37B |
| October 02, 2026 | 14.36B |
| October 01, 2026 | 14.32B |
| September 30, 2026 | 14.36B |
| September 29, 2026 | 14.56B |
| September 28, 2026 | 14.69B |
| September 25, 2026 | 14.40B |
| September 24, 2026 | 14.74B |
| September 23, 2026 | 14.24B |
| September 22, 2026 | 15.19B |
| September 21, 2026 | 15.19B |
| September 18, 2026 | 15.13B |
| September 17, 2026 | 15.28B |
| September 16, 2026 | 15.85B |
| September 15, 2026 | 15.33B |
| September 14, 2026 | 16.98B |
| September 11, 2026 | 16.89B |
| September 10, 2026 | 16.74B |
| September 09, 2026 | 16.71B |
| September 08, 2026 | 17.32B |
| September 04, 2026 | 17.35B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| BioMarin Pharmaceutical, Inc. | 14.55B |
| Novo Nordisk A/S | 152.68B |
| Genmab A/S | 34.93B |
| Zealand Pharma A/S | 407.51M |
| Evaxion AS | 15.96M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 85.11M |
| Revenue (Quarterly) | 425.30M |
| Total Expenses (Quarterly) | 340.19M |
| EPS Diluted (Quarterly) | 1.239 |
| Gross Profit Margin (Quarterly) | 91.21% |
| Profit Margin (Quarterly) | 20.01% |
| Earnings Yield | 5.64% |
| Operating Earnings Yield | 1.42% |
| Normalized Earnings Yield | 5.641 |